The Cryobank Market in 2026

A sperm bank is not a clinic and it is certainly not a financial services firm. It is a regulated reproductive-tissue business: you recruit and screen donors, freeze and store semen in liquid nitrogen, and sell vials to recipients and fertility clinics. The plan that wins funding treats the operation as exactly that, because the economics, the licensing, and the risks all flow from the tissue, not from generic small-business assumptions.

The global sperm bank market reached $5.92 billion in 2025 and is forecast to grow to about $7.2 billion by 2031 at a 3.31% compound annual rate, according to Mordor Intelligence, 2025. Other analysts model faster growth: one press release cites a 7.9% CAGR, so a defensible plan should present a range rather than a single hero figure.

Three structural facts shape the opportunity. First, sperm storage alone accounts for about 45.9% of market revenue, which tells you that recurring storage fees, not just one-off vial sales, are central to a durable model (Mordor Intelligence, 2025). Second, cancer patients banking before chemotherapy or radiation make up roughly 30.2% of end users, so medical fertility preservation is a large, referral-driven segment distinct from donor-sperm buyers. Third, demand is propped up by long-run trends: declining sperm parameters, later parenthood, single women by choice, and same-sex couples building families.

Supply, meanwhile, has consolidated. The number of US sperm banks fell from 29 in 1996 to roughly 16 by 2024, two of them nonprofits, per the Center for Genetics and Society, 2024. A thinner field of established names means a new entrant competes less on raw count and more on donor catalogue quality, identity-release options, and turnaround. The market also remains fragmented at the top: no single operator controls more than a mid-single-digit share, which is why a focused, well-positioned newcomer can carve out room.

Where the buyers are

Your plan should segment demand precisely. Recipients buying donor vials want a deep, diverse, well-documented catalogue and clear identity-release terms. Fertility clinics want reliability and chain-of-custody integrity so a vial arrives viable and correctly labelled. Personal-storage clients, including cancer patients and men ahead of a vasectomy or deployment, want secure, monitored long-term storage and simple annual billing. Each segment converts through a different channel, and the financial model should reflect that the storage book compounds while vial sales scale with catalogue depth.

Reading the competitive set

The established players define what buyers expect. California Cryobank and Fairfax Cryobank anchor the premium US end, with vials around $1,895 to $2,195 and deep, heavily documented catalogues; Fairfax has operated since 1986. Seattle Sperm Bank sits a notch below at roughly $1,395 per unit. Cryos International, the largest sperm and egg bank globally, competes on catalogue breadth and international shipping, with entry pricing from about EUR 40. The Sperm Bank of California, a nonprofit that pioneered identity-release in 1983, competes on mission and openness rather than price. In the UK, the London Sperm Bank is the dominant identity-release provider. A newcomer does not beat this field on scale; it wins by going deep on a defined niche, such as ethnically specific donor profiles, faster fertility-preservation turnaround for oncology referrals, or an unusually transparent identity-release experience. The plan should name the segment it will own and explain why an established operator will not simply copy it overnight.

Questions Founders Ask First

These are the questions that come up in nearly every early conversation about opening a cryobank. Short, candid answers up front; the financial detail follows in the sections below.

How do sperm banks actually make money?

Two engines. The first is vial sales: a cleared donor's frozen samples are split into individual vials and sold for insemination or IVF. The second is storage: clients and the bank's own inventory generate annual fees. A healthy plan models both, because vial revenue is lumpy and catalogue-dependent while storage revenue is recurring and predictable.

How much do sperm donors get paid?

It depends entirely on jurisdiction. In the US, donors are compensated: California Cryobank advertises around $75 per acceptable donation and up to $1,500 a month for committed donors. In the UK, paying for sperm is illegal; donors receive only expenses, capped at £45 per visit by the HFEA. Australia and Canada are also altruistic-only. This single rule reshapes the entire cost base, so never copy a US donor-cost line into a UK or Commonwealth plan.

How many vials does one donor produce?

A productive cleared donor commonly yields between 100 and 200 sellable vials across a year of donations, subject to semen quality and freeze/thaw survival. Family-limit rules then cap how many convert into sales in a given market; the UK restricts a donor to 10 families. Throughput per donor is an inventory question, not a marketing one.

Why is there a six-month wait before selling?

FDA rules require anonymous-donor semen to be quarantined and the donor retested for communicable diseases at least six months after donation before release. That is a regulatory safety window, and it is also the single biggest cash-flow trap in the business: you fund recruitment, screening and storage for half a year before the first vial earns a cent.

What It Costs to Open a Sperm Bank

Standing up a compliant cryobank typically takes $250,000 to $1.2 million in the US, or roughly £200,000 to £900,000 in the UK. The spread is wide because it depends on whether you build a fresh andrology lab or partner with an existing one, how large a launch donor cohort you screen, and how much redundant cryostorage you install. The number most first-time founders underestimate is not equipment; it is the working capital needed to bridge the six-month quarantine.

Cost breakdown

• Andrology and cryolab fit-out: $90K-$420K (£70K-£330K), clean processing area, vapor-phase liquid-nitrogen dewars, alarmed and redundant storage
• Lab equipment: $45K-$160K (£35K-£125K), CASA semen analyzer, phase-contrast microscopes, centrifuges, controlled-rate freezing
• Donor recruitment and infectious-disease testing: $40K-$140K (£30K-£110K) for the first cohort, at roughly $1,500-$3,500 per donor screened
• FDA registration + CLIA lab compliance (US) / HFEA licence + inspection (UK): $15K-$60K (£10K-£45K)
• Quality system, SOPs, legal, consent and donor-ID infrastructure, donor CRM: $25K-$95K (£18K-£70K)
• Working capital across the six-month quarantine: $45K-$220K (£35K-£170K)

Most generic guides stop at premises and equipment. The number that actually decides whether the business survives Year 1 is the quarantine bridge: budget it as its own line, fund it explicitly, and show lenders you can carry the donor pipeline before vial revenue switches on.

Why US and UK budgets diverge

The same facility costs different amounts to run depending on jurisdiction, and not only because of currency. In the US, donor compensation is a real recurring cost from day one, and multi-state distribution multiplies licensing spend. In the UK, donors are not paid, so the equivalent budget shifts into a larger, slower recruitment effort and the £45 expense reimbursement. A plan that simply converts dollars to pounds will misstate the cost base; the line items themselves move. The lean end of the range assumes a partnership with an existing andrology lab, which removes much of the fit-out capital, while the top of the range assumes a fully owned, purpose-built facility with redundant storage.

Lab & Cryostorage Equipment

The asset base of a cryobank is an andrology laboratory plus a cryogenic vault. Getting this list right matters for two reasons: it is most of the capital budget, and inspectors will check that the storage and testing chain meets the standard before they license you. The price bands below are planning ranges, not quotes.

• Vapor-phase LN2 storage dewars: $8K-$30K each, vapor-phase storage avoids submerging samples in liquid and reduces cross-contamination risk; plan for redundancy so no single tank holds the whole inventory
• Liquid-nitrogen supply and auto-fill system: $10K-$45K, bulk supply, transfer hoses, and an automated top-up loop with low-level alarms
• CASA (computer-assisted semen analysis) system: $25K-$70K, objective motility, concentration and morphology readings that hold up to clinical scrutiny
• Controlled-rate freezer or cryoprotectant freezing kit: $12K-$40K, repeatable freeze curves protect post-thaw survival
• Phase-contrast microscope, centrifuges, micropipettes, biosafety cabinet: $15K-$55K combined
• 24/7 temperature and LN2-level monitoring with remote alarms: $5K-$20K, a single overnight failure can destroy years of inventory, so this is non-negotiable, not optional
• Sample labelling, barcoding and chain-of-custody software: $8K-$30K, mislabelling is one of the most serious failures a tissue establishment can have
• Backup power (UPS plus generator) for the storage and monitoring stack: $10K-$40K

Redundancy is the theme. Equipment suppliers familiar to this niche include Hamilton Thorne and Microptic for CASA systems, and Chart Industries (MVE) and Cryotherm for storage dewars. Specify backups for storage, power and monitoring, because the inventory is irreplaceable and partly held in quarantine.

How a Sperm Bank Makes Money

Revenue comes from a small number of clear streams, and the plan should size each one separately rather than blending them into a single "sales" figure.

• Donor vial sales: the core line. US vials commonly sell for $1,195-$2,195 depending on preparation (ICI versus IUI) and identity-release status; the peer-reviewed Fertility and Sterility, 2025 cost analysis puts the median IUI vial at $1,625. UK vials run £200-£1,000.
• Annual storage fees: recurring revenue of roughly $200-$700 per client per year, the compounding base of the business.
• Personal fertility-preservation banking: first-sample processing around $550 plus annual storage, often referred by oncology and urology.
• Ancillary services: extended donor profiles, photo or audio sets, sibling registries, and shipping ($200-$400 per order).

Pricing is rising fast. The same Fertility and Sterility study found vial prices climbed 40% to 80% between 2023 and 2025, driven partly by demand for identity-release donors. That gives a new entrant pricing headroom, but it also raises buyer expectations on donor documentation.

Do not overlook the storage book. Each personal-storage client and each donor sample in inventory pays an annual fee against a largely fixed monitoring cost, so the storage line behaves like an annuity: it is small early but compounds and smooths the lumpiness of vial sales. A bank that adds a few hundred storage clients a year builds a base of recurring revenue that lenders value highly because it is predictable and sticky, with low churn once a client has committed samples to a facility. The plan should model storage as its own cohort, with an acquisition cost, an annual fee, and a renewal rate, rather than folding it into vial revenue.

A worked Year-1 example

Take a launch catalogue of 12 cleared donors. If each yields roughly 140 sellable vials over the year and the bank sells, after a realistic ramp, about 640 vials at a blended $1,400 net of shipping, that is ~$896,000 in vial revenue. Layer on 900 personal-storage clients at $300 a year and you add $270,000 of recurring revenue, for roughly $1.0M-$1.2M in Year 1. Gross margin on vials lands in the 55-75% band once the catalogue exists; net margin settles around 25% after donor compensation, lab staff, compliance and the carrying cost of quarantine. The decisive variables are catalogue depth and how quickly storage clients accumulate.

This is the model competitors gloss over. Most guides quote a vial price and stop. The number that drives the business is contribution per cleared donor after screening and quarantine cost, multiplied by how many of that donor's vials you can actually sell before family limits bind.

How the Operation Runs Day to Day

Operations are where a cryobank's margin and its compliance record are won or lost. The plan should walk a lender or inspector through the full lifecycle of a sample, because that lifecycle is also the cost structure.

The donor recruitment funnel

Recruitment is the top of the inventory pipeline, and it is far harder than founders expect. After advertising, an applicant goes through an initial questionnaire, a semen analysis, a detailed medical and family history, genetic screening, and infectious-disease testing. Acceptance rates are often under 5% of applicants once all of that is applied, so the marketing budget has to fund a wide funnel to clear a handful of donors. The plan should model cost-per-cleared-donor, not cost-per-applicant, and treat each cleared donor as a capital asset that will generate vial revenue for years.

Processing, freezing and quarantine

Each accepted donation is analysed, processed, divided into vials, mixed with cryoprotectant, and frozen using a controlled-rate curve before going into vapor-phase liquid-nitrogen storage. Anonymous-donor vials then sit in quarantine until the donor is retested at the six-month mark. Throughout, chain-of-custody records and barcoding must be flawless; a mislabelled vial is among the most serious failures a tissue establishment can commit, and it is exactly what FDA and HFEA inspections probe.

Order fulfilment and storage

When a recipient or clinic selects a donor, vials are pulled, documented, packed in a dry-shipper that holds cryogenic temperature for several days, and shipped with tracking. Personal-storage clients are billed annually and their samples monitored continuously. The operational KPIs the plan should track are post-thaw survival rate, cost per cleared donor, vials sold per donor, storage-client churn, and the temperature-excursion count, which should be zero.

Team and milestones

A launch team usually centres on an embryologist or andrologist as lab director, a quality and compliance lead, donor-services and recruitment staff, and a customer-facing coordinator, with a named medical practitioner overseeing donor screening where regulation requires it. Year-one milestones run in sequence: secure the licence or registration, stand up the lab and storage, open donor recruitment, clear the first cohort through quarantine, make the first vial sale, and reach a storage-client base that covers fixed monitoring costs. Sequencing matters because the regulatory steps gate everything downstream.

Reaching Donors and Recipients

A cryobank has to market on two fronts at once, and the plan should treat them as separate campaigns with separate budgets, because the audiences, the channels and the success metrics do not overlap.

Donor acquisition

Donor recruitment skews to where eligible men concentrate: university towns and large cities. Channels that work include targeted social and search ads, campus outreach, and referral incentives where the law permits payment. Because acceptance rates are low, the metric that matters is cost per cleared donor, and the plan should show how a wide top-of-funnel converts into a small, high-quality catalogue. In altruistic-only markets such as the UK, Australia and Canada, the message shifts from compensation to purpose, and recruitment is slower and more expensive per cleared donor as a result.

Recipient and clinic acquisition

On the buyer side, demand is intent-driven and research-heavy. Recipients compare catalogues, identity-release terms and success rates for weeks before purchasing, so search visibility, a strong donor-search experience, and transparent documentation convert better than discounting. Fertility-clinic relationships are a second, higher-volume channel: a clinic that trusts your chain of custody will order repeatedly. Oncology and urology referral pathways feed the fertility-preservation segment. Tie each channel to a realistic acquisition cost, a conversion rate, and a repeat-purchase or storage-renewal assumption so the sales forecast rests on a real funnel rather than a flat growth percentage.

Funding & SBA Loan Data

A sperm bank is capital-intensive and slow to first revenue, so the funding stack usually blends sources. In the US, the SBA 7(a) programme lends up to $5 million and is the most common route for a healthcare facility build-out; the related SBA 504 programme suits real estate and major equipment such as cryostorage and lab fit-out. Medical-equipment financing and leasing can spread the cost of dewars, freezers and the CASA system so they are not funded entirely from equity.

Lenders underwriting this niche look closely at three things specific to a cryobank: a credible donor-recruitment plan, evidence that the founder understands FDA or HFEA obligations, and a cash-flow forecast that funds the quarantine gap. The plan should map the raise to a 9-month pre-revenue runway, not a 3-month one, because the regulatory timeline is fixed and cannot be compressed.

In the UK, government-backed Start Up Loans of up to £25,000 at 6% fixed help at the founder level, but a full cryobank usually needs bank debt or angel equity on top. Whichever route you choose, the document a lender signs off is a financial model that proves you can survive to first revenue.

Regulation: FDA, HFEA & Beyond

This is the section where a sperm bank plan is made or broken, and where generic templates go badly wrong by treating the business like an ordinary clinic. Donated sperm is regulated as human tissue, and the rules differ sharply by country.

United States

The FDA regulates donor sperm as a human cell, tissue and cellular and tissue-based product (HCT/P). The core obligations:

• Register the establishment with the FDA and list your HCT/Ps under 21 CFR Part 1271, generally within five days of starting operations
• Make a donor-eligibility determination based on screening and infectious-disease testing under 21 CFR Part 1271, Subpart C
• Test for HIV-1 and HIV-2, hepatitis B, hepatitis C, syphilis, chlamydia and gonorrhea, plus HTLV-I/II and CMV for sperm donors
• Quarantine anonymous-donor semen and retest the donor at least six months after donation before release, under 21 CFR 1271.85(d)
• Use a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA, 42 CFR Part 493) for the required testing

Compliance is actively enforced. The FDA issues warning letters to sperm establishments that fall short on donor eligibility and testing, so the plan should treat the quality system as a core deliverable, not paperwork.

State rules layer on top of the federal baseline. New York, for example, requires a separate tissue-bank licence and imposes its own inspection regime through the state health department, which is materially more demanding than FDA registration alone. California and several other states add their own requirements for reproductive-tissue establishments. A plan that intends to ship vials nationwide should map which states the bank will be licensed to distribute into, because each adds cost and timeline, and a buyer in a strict state cannot legally receive a vial from an unlicensed establishment.

United Kingdom

A UK sperm bank cannot procure, test, process, store or distribute gametes without a licence from the Human Fertilisation and Embryology Authority under the Human Fertilisation and Embryology Act.

• HFEA licence application fee of roughly £500-£750, plus ongoing regulated and inspection fees
• A new clinic gets a two-year licence; established clinics can apply for up to four years
• Identity-release only since 2005: donor-conceived people can access identifying donor information at 18
• A 10-family limit per donor caps real-world vial throughput in the UK market
• Altruistic model: paying for sperm is unlawful; donor reimbursement is capped at £45 per clinic visit

Other jurisdictions

• Australia: RTAC accreditation through the Fertility Society of Australia and New Zealand against a Code of Practice, under NHMRC ART ethical guidelines, with a NATA-compliant lab. There is no single federal ART law, so state and territory rules add family limits and identity-disclosure requirements. Payment for donation is prohibited.
• Canada: donor semen is regulated as a drug under the Food and Drugs Act and the Safety of Sperm and Ova Regulations (SOR/2019-192), overseen by Health Canada. The Assisted Human Reproduction Act bans buying sperm; donors may only be reimbursed documented expenses.

The practical takeaway: a US plan can build on paid donor recruitment and faster supply, while a UK, Australian or Canadian plan must build supply on altruistic recruitment and bake in family limits. These are not cosmetic differences; they change the cost base, the marketing approach and the revenue ceiling.

Mistakes That Sink Cryobank Plans

Across reproductive-tissue plans, the same avoidable errors show up. Catch them before a lender or the regulator does.

• Booking revenue from month one. Anonymous-donor vials cannot be sold until the six-month quarantine and retest are complete. A plan that shows vial income in Q1 is not credible and signals the founder has not read the rules.
• Confusing the FDA HCT/P regime with a clinic licence. A sperm bank is a tissue establishment, not a medical practice. The registration, testing and record-keeping obligations are specific and inspected.
• Copying a US donor-cost line into a UK or Commonwealth plan. Paying donors is unlawful in the UK, Australia and Canada. The supply model there is altruistic recruitment, and the marketing and cost base change accordingly.
• Under-investing in storage redundancy. One failed alarm or one tank failure can wipe out the entire inventory, including samples mid-quarantine. Monitoring, backup power and tank redundancy are core spend, not extras.
• Assuming donors are easy to sign. Acceptance rates are often under 5% of applicants once medical, genetic and semen-quality screening is applied. Catalogue depth is hard-won inventory; budget the recruitment funnel realistically.
• Ignoring family limits. Caps such as the UK's 10-family rule constrain how many of a donor's vials convert into sales in one market, so per-donor revenue is bounded and must be modelled, not assumed unlimited.

Cryobank Terms Worth Knowing

This is a jargon-heavy field, and lenders notice when a founder uses the language correctly. A few terms that recur throughout a sperm bank plan:

• HCT/P: human cell, tissue and cellular and tissue-based product, the FDA classification that brings donor sperm under 21 CFR Part 1271.
• Cryopreservation: freezing samples, typically in vapor-phase liquid nitrogen at around minus 196 degrees Celsius, so they remain viable for years.
• CASA: computer-assisted semen analysis, the objective measurement of sperm motility, concentration and morphology.
• ICI vs IUI vial: intracervical insemination vials are unwashed; intrauterine insemination vials are washed and prepared for direct uterine placement, and usually priced higher.
• Identity-release (open) donor: a donor whose identifying information can be released to donor-conceived people, mandatory in the UK and increasingly demanded in the US.
• Quarantine and retest: the FDA requirement to hold anonymous-donor samples and retest the donor at six months before release.
• Family limit: the cap on how many families one donor may help create, such as the UK's limit of 10.
• Dry shipper: a vapor-phase nitrogen container that keeps vials at cryogenic temperature in transit for several days.

Sample Business Plan Preview

Here is the structure and the financial outputs a buyer receives. These visual mockups are generated from the same assumptions used throughout this page.

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary, Your cryobank at a glance, written to hook lenders and investors in 60 seconds
• Company Overview, Legal structure, ownership, location, licensing status and founding story
• Industry Analysis, Market size, growth, donor-demand trends and the regulatory regime
• Customer Analysis, Recipients, fertility clinics and personal-storage clients, with buying criteria for each
• Competitor Analysis, Mapping against established names and your catalogue and identity-release differentiation
• Marketing Plan, Donor recruitment and recipient acquisition channels and messaging
• Operations Plan, Lab workflow, quarantine handling, chain of custody, staffing and milestones
• Management Team, Founder and embryology bios, advisory board and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, a startup capital table, and a quarantine-aware Year-1 monthly view built around donor yield, vial price and storage revenue.

For closely related niches, see our fertility clinic business plan template and our stem cell banking business plan template, or browse all free business plan templates.

Frequently Asked Questions

Useful Links & Resources

These links were preserved from the live page so important references and partner links are not lost during the page refresh.

• Facebook
• Instagram
• LinkedIn
• YouTube